Center for Health Care Research and Policy, Population Health and Equity Research Institute, The MetroHealth System, Cleveland, OH, USA.
School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Ren Fail. 2024 Dec;46(2):2350767. doi: 10.1080/0886022X.2024.2350767. Epub 2024 Aug 1.
Screening for depression can be challenging among hemodialysis patients due to the overlap of depressive symptoms with dialysis or kidney disease related symptoms. The aim of this study was to understand these overlapping symptoms and develop a depression screening tool for better clinical assessment of depressive symptoms in dialysis patients.
We surveyed 1,085 dialysis patients between March 1, 2018 and February 28, 2023 at 15 dialysis facilities in Northeast Ohio with the 9-item patient health questionnaire (PHQ-9) and kidney disease quality of life (KDQOL) instrument. To evaluate overlap across questionnaire items, we used structural equation modeling (SEM). We predicted and transformed factor scores to create a hemodialysis-adjusted PHQ-9 (hdPHQ-9). In exploratory analysis ( = 173), we evaluated the performance of the hdPHQ-9 relative to the PHQ-9 that also received a Mini-International Neuropsychiatric Interview.
Our study sample included a high percentage of Black patients (74.6%) and 157 (14.5%) survey participants screened positive for depression (PHQ-9 ≥ 10). The magnitude of overlap was small for (respectively, PHQ-9 item with KDQOL item) fatigue with washed out, guilt with burden on family, appetite with nausea and movement with lightheaded. The hdPHQ-9 showed reasonably high sensitivity (0.81 with 95% confidence interval [CI] 0.58, 0.95) and specificity (0.84 with 95% CI 0.77, 0.89); however, this was not a significant improvement from the PHQ-9.
There is little overlap between depressive symptoms and dialysis or kidney disease symptoms. The PHQ-9 was found to be an appropriate depression screening instrument for dialysis patients.
由于透析相关症状与抑郁症状存在重叠,对血液透析患者进行抑郁筛查具有一定挑战性。本研究旨在了解这些重叠症状,并开发一种抑郁筛查工具,以更好地评估透析患者的抑郁症状。
我们于 2018 年 3 月 1 日至 2023 年 2 月 28 日期间在俄亥俄州东北部的 15 家透析中心对 1085 名透析患者进行了调查,使用 9 项患者健康问卷(PHQ-9)和肾脏疾病生活质量(KDQOL)量表。为了评估问卷项目之间的重叠,我们使用结构方程模型(SEM)。我们预测并转换因子得分,以创建血液透析调整后的 PHQ-9(hdPHQ-9)。在探索性分析(n=173)中,我们评估了 hdPHQ-9 与接受迷你国际神经精神访谈的 PHQ-9 的性能。
我们的研究样本中,黑种人患者比例较高(74.6%),157 名(14.5%)参与者 PHQ-9 筛查阳性(PHQ-9≥10)。疲劳与无力、内疚与家庭负担、食欲与恶心、运动与头晕之间的重叠程度较小。hdPHQ-9 具有较高的灵敏度(0.81,95%置信区间[CI] 0.58,0.95)和特异性(0.84,95% CI 0.77,0.89);然而,与 PHQ-9 相比,这并没有显著提高。
抑郁症状与透析或肾脏疾病症状之间几乎没有重叠。PHQ-9 被发现是透析患者的一种合适的抑郁筛查工具。